Pulmonary arterial hypertension leads to significant impairment in haemodynamics, right
heart function, exercise capacity, quality of life and survival. Current therapies have …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

2022 ESC/ERS pulmonary hypertension guidelines incorporate changes and adaptations
focusing on clinical management https://bit. ly/3QtUvb4

Background Risk stratification plays an essential role in the management of patients with
pulmonary arterial hypertension (PAH). The current European guidelines propose a three …

Background Among patients meeting diagnostic criteria for idiopathic pulmonary arterial
hypertension (IPAH), there is an emerging lung phenotype characterised by a low diffusion …

Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a
progressive increase in pulmonary vascular resistance and eventual right ventricular (RV) …

Pulmonary hypertension (PH) associated with chronic lung disease (CLD) is both common
and underrecognised. The presence of PH in the setting of lung disease has been …

Background Since 2015, the European pulmonary hypertension guidelines recommend the
use of combination therapy in most patients with pulmonary arterial hypertension (PAH) …

Although it is a rare disease, the number of available therapeutic options for treating
pulmonary arterial hypertension has increased since the late 1990s, with multiple drugs …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …